Pharmacological intervention study with L-arginin in prevention of diabete type II in patients affected by metabolic syndrome.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004639-24-IT

Enrollment

294

Registered

2005-10-26

Start date

2005-10-24

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome treatment for diabet type II prevention MedDRA version: 6.1 Level: HLGT Classification code 10037008

Interventions

Trade Name: BIOARGININA*OS1,66G/20ML20FL Pharmaceutical Form: Oral solution CAS Number: 1119-34-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 166-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026